Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
208
resultados
Última actualización
02/02/2026 [06:51:00]
Resultados 25 a 50 de 208
Resumen de: CN121421991A
本发明的目的在于提供一种酸响应型类风湿性关节炎靶向治疗纳米制剂及其合成方法和应用，属于纳米生物医学材料制备技术领域，所述纳米制剂为Zn/SiO2‑;MTX@M2，其通过油水两相法合成具有蒲公英状结构的Zn/SiO₂纳米颗粒，利用该颗粒的大孔径特性负载甲氨蝶呤，并在外层包覆M2巨噬细胞膜制备而成。该纳米制剂借助M2巨噬细胞膜的炎症趋化性与同源靶向作用，具有良好的生物相容性、稳定性及对类风湿性关节炎部位的靶向能力。在酸性微环境下，纳米颗粒可响应释放锌离子与药物，从而实现针对类风湿性关节炎的安全有效治疗。
Resumen de: CN121426693A
本发明提供了一种脂质化合物或其药学上可接受的盐及其制备方法、脂质纳米颗粒和应用，属于生物医药技术领域。该脂质化合物或其药学上可接受的盐，具有式（I）所示的结构式，式（I）所示的结构如说明书中所示。R为取代或未取代C1~C10烷基、取代或未取代C2~C10醚；X为C1~C20直链或支链烷基；Y为C1~C20直链烷基，或者C2~C20直链或支链不饱和脂肪烃基；A为C1~C5亚烷基酯基；Z为C11~C18支链烷基；在上述取代或未取代基团上具有取代基的情况下，取代基选自羟基。
Resumen de: CN121422199A
本发明提供了一种协同敲低PCSK9基因表达的mRNA疫苗，属于生物医药领域。所述mRNA疫苗包含靶向沉默PCSK9基因的siRNA、编码卵清蛋白(OVA)的mRNA和含氟化修饰的聚乙二醇化脂质的脂质纳米颗粒。所述siRNA通过下调PCSK9基因的表达量来提高MHCⅠ复合体的水平；所述mRNA则提高细胞内抗原的表达水平；所述脂质纳米颗粒则提高了mRNA的递送效率，为所述疫苗发挥疗效奠定了基础。本发明证明了所述mRNA疫苗能显著提高肿瘤细胞的抗原呈递效率，强烈诱导机体产生免疫反应，显著抑制肿瘤生长，延长荷瘤小鼠的寿命；且证实了所述siRNA和mRNA组合具有协同增效的作用。
Resumen de: AU2024303397A1
Provided is a rapidly-metabolized lipid compound. The present invention relates in particular to a compound represented by formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and a composition thereof in delivering nucleic acids.
Resumen de: WO2026021576A1
A nucleic acid lipid nanocarrier, a preparation method therefor, and use thereof. First, provided is a nanocarrier composition for a nucleic acid drug. On the basis that the total molar amount of lipids in the composition is 100%, the composition comprises the following lipid components: greater than or equal to 40% and less than or equal to 50% of ionizable lipid; greater than or equal to 0.5% and less than or equal to 3.0% of PEG-modified lipid; greater than or equal to 30% and less than or equal to 44.5% of steroid; and greater than 15% and less than 22% of helper phospholipid. Also provided are use of the composition in the preparation of a nucleic acid drug nanocarrier and the prepared nucleic acid-loaded drug. The nucleic acid drug nanocarrier can target a treatment site, and the non-liver-targeting lipid nanocarrier has low liver metastasis.
Resumen de: WO2026022651A1
The current invention involves a method of mixing POP with a polysaccharide to obtain an improved injectable tissue matrix. POP is a partially ordered polypeptide and a polysaccharide, in this instance, comprises at least one glycosaminoglycan. The invention involves mixing these compounds in an injectable tissue matrix to increase volume retention, vascularization, and remodeling immune response, all of which are characteristics that would be useful for an injectable dermal filler, and in plastic and reconstructive procedures.
Resumen de: WO2026022658A1
The invention pertains to pharmaceutical formulations, particularly sustained-release nanoparticle injections of nomegestrol acetate. These formulations are designed as lyophilized powder, enhancing the solubility, bioavailability, and therapeutic efficacy of nomegestrol acetate for medical applications. These pharmaceutical formulations are intended for diseases responsive to nomegestrol treatment, such as hormone replacement therapy. The lyophilized powder formulation is easily reconstituted and administered, improving overall patient experience and treatment outcomes
Resumen de: WO2026020697A1
The present invention pertains to the technical field of novel biomaterials. Disclosed is use of hyaluronic acid in improving the performance of a polysaccharide-polypeptide composite hydrogel. The present invention, on the basis of the self-assembly characteristics of polypeptides, prepares polysaccharide-polypeptide composite hydrogels with hyaluronic acid (HA) at different concentrations. It has been verified that compared to a single polypeptide hydrogel free of HA, HA reduces the mechanical properties of the composite gels, but can still slow the degradation of the composite hydrogels and improve the stability thereof. HA can also improve the ability of the composite hydrogels to load quercetin and hesperidin, playing a role in slowing the in vitro release of the two, which is conducive to the sustained release of active substances. Moreover, the addition of HA does not affect the secondary structures and micro-nano structures of the composite hydrogels, and can also improve the strength of non-covalent interactions between molecules, improving the stability of the composite hydrogels. The present invention explores the effect of HA on the performance of the composite hydrogels and provides a theoretical basis for the research of hydrophobic drug delivery carriers.
Resumen de: WO2026020280A1
The present disclosure belongs to the technical field of block copolymers, and specifically relates to an amphiphilic block copolymer, a stereocomplex, and a preparation method therefor and the use thereof. The amphiphilic block copolymer contains a polyester block and a water-soluble polymer block. By forming a monomer of the polyester block and introducing a second monomer having stereoregularity on the premise that raw materials, such as D- and L-lactide, are used as a first monomer, the stability of the amphiphilic block copolymer can be improved; in addition, the water solubility or self-dispersibility thereof are still maintained, micelles or nanoparticles are formed, and high drug loading capacity is maintained.
Resumen de: WO2026022743A1
The subject of the present invention is N,N'-bis(acryloyl)selenocystine represented by formula 1, a method of its manufacturing, and its use as a crosslinking agent in polymerisation reactions, preferably in nanogel polymerisation reactions. Another subject of the invention is a method of manufacturing a p(NIPA-BISeSe) nanogel, and the use of the p(NIPA-BISeSe) nanogel obtained by this method as a carrier of drugs, preferably anticancer drugs.
Resumen de: WO2026022261A1
The present invention relates to a lipid system comprising: a) at least one oil, b) at least one ionizable lipid, c) at least one sphingolipid, and d) at least one lipid-polymer, with the proviso is that the lipid system does not comprise cholesterol. The present invention also uses of the lipid system in therapy.
Resumen de: US20260028323A1
The present application disclosed a compound of formula (I) and a salt and a stereoisomer thereof, wherein each variable is as defined in the specification. The present application also disclosed a nanoparticle composition comprising the compound or a salt or a stereoisomer thereof, and the use of the nanoparticle composition for delivering active agents.
Resumen de: US20260028349A1
Photodynamic therapy (PDT) is a minimally invasive treatment that involves the administration of a light-activatable drug followed by light activation of the lesion to produce reactive oxygen species that kill cancer cells. VISUDYNE®, a liposomal formulation of benzoporphyrin derivative (BPD) photosensitizer, is clinically approved for PDT of ocular diseases and is now being tested for PDT and imaging of pancreatic, brain, and other cancers. While VISUDYNE® improves the pharmacokinetics of BPD, it lacks treatment selectivity. This present disclosure is directed to dBPD, dBPD nanoparticles, and preparation and use thereof that provide cancer treatment selectivity for cancers characterized by overexpression of folate receptor (FR).
Resumen de: WO2026022713A1
The invention relates to nanoparticles of GdaTbbF3, where a = 0.50 to 0.95, b = 0.05 to 0.50 and a + b = 1, which are surface-modified by at least one biocompatibility ligand and by at least one photosensitizer that absorbs in the same wavelength band as the emission wavelength band of terbium, namely between 520 and 560 nm.
Resumen de: WO2026022656A2
The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.
Resumen de: WO2026021698A1
The present invention generally relates to nucleic acid particles, in particular nucleic acid-lipid particles, comprising targeting moieties that are bound to the particles, and to pharmaceutical compositions containing the nucleic acid particles and their uses in medicine.
Resumen de: US20260028406A1
Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.
Resumen de: US20260028376A1
In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction. In some embodiments, the invention provides mRNA sequences of said HIV-1 immunogens.
Resumen de: US20260028317A1
The present application is directed to a nanocage of Formula (I): wherein A and R are as described herein. The present application is also directed to an efficient process for preparation of a nanocage of Formula (I), which allows for efficient scale-up of the nanocage synthesis. Furthermore, this new process allows for rapid nanocage diversification, due a newly introduced late-stage functionalization method.
Resumen de: US20260028310A1
The invention relates to a compound, a lipid compound nanoparticle, a nucleic acid nanoparticle complex, a pharmaceutical composition and uses thereof in the drug delivery field, and belongs to the fields of biomedicine and biotechnology. The structure of the compound is shown as formula A. The compound, lipid compound nanoparticle or nucleic acid nanoparticle complex provided herein has the advantages of good biocompatibility, high transfection efficiency, low toxicity and excellent technical effects.
Resumen de: US20260027492A1
A porous hollow fiber membrane based anti-solvent crystallization (AsCr) process is disclosed. The process involves injecting an anti-solvent from a bore of a hollow fiber membrane into a shell side where a feed solution containing a solution containing a material, e.g., an API, is flowing. The shell-side feed solution flows perpendicular to the hollow fiber length; the shell side liquid is in cross flow across the hollow fiber membranes. Multiple HFM modules may be positioned in series with nanocrystal suspension product from one module fed to the next module that is independently fed with an anti-solvent. The crossflow HFM based continuous AsCr technique disclosed herein could result in continuous nanocrystal production of APIs.
Resumen de: US20260027200A1
Provided are a poxvirus mRNA vaccine and a use. Specifically, provided is an isolated mRNA molecule, comprising a coding region, the coding region coding a target protein, and the target protein comprising the following four proteins: vaccinia virus surface antigens A27, L1, A33, and B5, wherein every two adjacent proteins are independently directly linked or linked by identical or different linkers. Animal immunization results show that the mRNA molecule has good candidate vaccine potential and provides an innovative idea for the development of poxvirus vaccines.
Resumen de: US20260027228A1
In one aspect, the disclosure relates to compounds methods for treating or preventing diseases associated with aberrant condensation of a biomolecule in a subject, the method including at least the step of contacting one or more cells in the subject with a fusion protein that includes a J domain protein and a targeting molecule, wherein the targeting molecule binds the biomolecule. In one aspect, the biomolecule can be a target protein that may be mutated and/or include one or more intrinsically disordered regions. In another aspect, the targeting molecule can be a nanobody, but other targeting molecules are also contemplated. In still another aspect, the disclosed method is useful for treating and/or preventing cancers such as blood cancers and non-small cell lung cancer. Also disclosed are methods for disrupting condensates in cell culture.
Resumen de: US20260027192A1
It pertains to a novel platform for the sustained release of Type-1 diabetes antigens. More specifically. it provides a combination of dual sized hydrogel particles for the delivery of Type-1 diabetes antigens and multi-component adjuvants to confer immune tolerance.
Nº publicación: US20260027229A1 29/01/2026
Solicitante:
ACCURE HEALTH INC [US]
ACCURE HEALTH INC
Resumen de: US20260027229A1
This disclosure provides an engineered delivery system, including a bacterial membrane vesicle derived from bacteria and one or more non-bacterial proteins for anchoring to the bacterial membrane vesicle.
BOPI
Sede Electrónica
